Economic evaluations of sunitinib versus interferon-alfa (IFN-α) in first-line metastatic renal cell carcinoma (mRCC)

被引：0
|
作者：
Remak, E.
Mullins, C. D.
Akobundu, E.
Charbonneau, C.
Woodruff, K.
机构：
[1] United BioSource Corp, London, England
[2] Univ Maryland, Sch Pharm, Baltimore, MD 21201 USA
[3] Pfizer Inc, New York, NY USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2007年 / 25卷 / 18期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
6607
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Economic evaluation of sunitinib vs. interferon-alfa (IFN-α) in first-line metastatic renal cell carcinoma (mRCC)
    Negrier, S.
    Remak, E.
    Brown, R.
    Kim, S. T.
    Charbonneau, C.
    Motzer, R. J.
    [J]. EJC SUPPLEMENTS, 2007, 5 (04): : 303 - 303
  • [2] OVERALL SURVIVAL WITH SUNITINIB VERSUS INTERFERON-ALFA (IFN-□) AS FIRST-LINE TREATMENT FOR METASTATIC RENAL CELL CARCINOMA (MRCC)
    Szczylik, C.
    Negrier, S.
    Oudard, S.
    Figlin, R. A.
    Hutson, T. E.
    Tomczak, P.
    Michaelson, M. D.
    Bukowski, R. M.
    Huang, X.
    Kim, S. T.
    Chen, I
    Motzer, R. J.
    [J]. EUROPEAN UROLOGY SUPPLEMENTS, 2009, 8 (04) : 182 - 182
  • [3] Sunitinib versus interferon-alfa (IFN-α) as first-line treatment of metastatic renal cell carcinoma (mRCC): Updated results and analysis of prognostic factors
    Motzer, R. J.
    Figlin, R. A.
    Hutson, T. E.
    Tomczak, P.
    Bukowski, R. M.
    Rixe, O.
    Bjarnason, G. A.
    Kim, S. T.
    Chen, I.
    Michaelson, D.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [4] Quality of life (QOL) with sunitinib versus interferon-alfa (IFN-α) as first-line therapy in patients with metastatic renal cell carcinoma (mRCC): Final results
    Cella, D.
    Michaelson, M. D.
    Cappelleri, J. C.
    Bushmakin, A. G.
    Charbonneau, C.
    Kim, S. T.
    Li, J. Z.
    Motzer, R. J.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [5] Economic evaluation of sunitinib vs. interferon-alfa (IFN-alfa) in first-line treatment of Metastatic Renal Cell Carcinoma (MRCC) in Colombia
    Godoy, J., I
    Cardona, A. F.
    Alvis, N.
    Arango, C. H.
    Romero, M.
    Spath, A.
    Ramirez, P.
    Caceres, H. A.
    Quijano, M. F.
    [J]. VALUE IN HEALTH, 2008, 11 (03) : A100 - A100
  • [6] OVERALL SURVIVAL WITH SUNITINIB VERSUS INTERFERON (IFN)-ALFA AS FIRST-LINE TREATMENT OF METASTATIC RENAL CELL CARCINOMA (MRCC)
    Negrier, S.
    Figlin, R. A.
    Hutson, T. E.
    Tomczak, P.
    Michaelson, M. D.
    Bukowski, R. M.
    Huang, X.
    Kim, S. T.
    Chen, I.
    Motzer, R. J.
    [J]. ANNALS OF ONCOLOGY, 2008, 19 : 190 - 190
  • [7] Overall survival with sunitinib versus interferon (IFN)-alfa as first-line treatment of metastatic renal cell carcinoma (mRCC)
    Figlin, R. A.
    Hutson, T. E.
    Tomczak, P.
    Michaelson, M. D.
    Bukowski, R. M.
    Negrier, S.
    Huang, X.
    Kim, S. T.
    Chen, I.
    Motzer, R. J.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [8] Characterizing prior nephrectomy patients with metastatic renal cell carcinoma (mRCC) treated with first-line sunitinib versus interferon-alfa
    Figlin, R. A.
    Hutson, T. E.
    Tomczak, P.
    Michaelson, M. D.
    Bjarnason, G. A.
    Lin, X.
    Lowenthal, S. Pitman
    Korytowsky, B.
    Matczak, E.
    Oudard, S.
    [J]. EUROPEAN JOURNAL OF CANCER, 2013, 49 : S644 - S645
  • [9] Phase III randomized trial of sunitinib malate (SU1 1248) versus interferon-alfa (IFN-α) as first-line systemic therapy for patients with metastatic renal cell carcinoma (mRCC).
    Motzer, R. J.
    Hutson, T. E.
    Tomczak, P.
    Michaelson, M. D.
    Bukowski, R. M.
    Rixe, O.
    Oudard, S.
    Kim, S. T.
    Baum, C. M.
    Figlin, R. A.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 2S - 2S
  • [10] Sunitinib plus interferon-alfa in the first-line treatment for metastatic renal cell carcinoma (mRCC): results of a dose-finding study
    Kondagunta, G. V.
    Hudes, G.
    Figlin, R.
    Wilding, G.
    Hariharan, S.
    Kempin, S.
    Fayyad, R.
    Hoosen, S.
    Motzer, R. J.
    [J]. EJC SUPPLEMENTS, 2007, 5 (04): : 305 - 305
12345